⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for metastatic prostate cancer

Every month we try and update this database with for metastatic prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With DocetaxelNCT01814150
Metastatic Lung...
Metastatic Brea...
Metastatic Gast...
Metastatic Pros...
Metastatic Blad...
18 Years - Meir Medical Center
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate CancerNCT01560923
Metastatic Pros...
Indoximod
Sipuleucel-T
Placebo
18 Years - Masonic Cancer Center, University of Minnesota
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response GenesNCT06439225
Metastatic Cast...
Metastatic Pros...
Docetaxel
Carboplatin
18 Years - Canadian Cancer Trials Group
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)NCT00684970
Metastatic Cast...
Hamsa-1™ TL-118
18 Years - Tiltan Pharma Ltd.
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate CancerNCT03230734
Metastatic Cast...
Radium-223
Docetaxel
18 Years - Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate CancerNCT00494338
Metastatic Pros...
Docetaxel
18 Years - Sanofi
PROState Pathway Embedded Comparative TrialNCT04400656
Prostate Cancer
Non-metastatic ...
Metastatic Pros...
Prostate Adenoc...
Metastatic Pros...
Prostate Cancer...
18 Years - Imperial College London
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057NCT02916537
Prostate Cancer
CTT1057
Prostatectomy
18 Years - Cancer Targeted Technology
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)NCT04332744
Metastatic Pros...
Enzalutamide
Talazoparib
18 Years - MedSIR
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsNCT02376296
Prostate Cancer
docetaxel
Blood draws
18 Years - Saladax Biomedical, Inc.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNCT04140526
Non Small Cell ...
Advanced Solid ...
Metastatic Mela...
Metastatic Head...
Metastatic Rena...
Metastatic Colo...
Sarcomas
Metastatic Pros...
Ovarian Cancer
Small Cell Lung...
Metastatic Brea...
Pancreas Cancer
Gastric Cancer
Esophageal Canc...
Gastroesophagea...
Cervical Cancer
Adenoid Cystic ...
Salivary Gland ...
Urothelial Carc...
ONC-392
Pembrolizumab
Docetaxel
18 Years - OncoC4, Inc.
Pazopanib, Docetaxel, Prednisone ProstateNCT01385228
Prostate Cancer
Pazopanib
Docetaxel
Pazopanib
Prednisone
Pegfilgrastim
18 Years - Duke University
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622
Prostate Cancer
talazoparib plu...
Placebo plus en...
18 Years - Pfizer
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate CancerNCT04887506
Metastatic Cast...
Metastatic Cast...
Metastatic Pros...
TAVT-45
Zytiga
Prednisone
18 Years - Tavanta Therapeutics
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerNCT04262154
Metastatic Pros...
Atezolizumab
Abiraterone
Prednisone
GnRH analog
Stereotactic Bo...
Enzalutamide
Follow up
18 Years - Memorial Sloan Kettering Cancer Center
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate CancerNCT02260817
Metastatic Pros...
11C-choline Inj...
18 Years - Global Isotopes, LLC d/b/a Zevacor Molecular
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.NCT05917470
Metastatic Cast...
ONCT-534
18 Years - Oncternal Therapeutics, Inc
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPCNCT03432949
Metastatic Pros...
Dexamethasone p...
- University Health Network, Toronto
A Journey Into Participation Patterns Among Metastatic Prostate Cancer PatientsNCT06009549
Metastatic Pros...
18 Years - Power Life Sciences Inc.
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate CancerNCT04220983
Metastatic Pros...
MR-Guided Prost...
18 Years - 90 YearsWeill Medical College of Cornell University
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateNCT05590793
Advanced Prosta...
Metastatic Pros...
Locally Advance...
Triptorelin pam...
18 Years - Ipsen
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)NCT04726033
Metastatic Pros...
64Cu-DOTA-TLX59...
- Telix Pharmaceuticals (Innovations) Pty Limited
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPCNCT01062503
Metastatic Pros...
Bone Metastasis
Zoledronic acid
18 Years - University Health Network, Toronto
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate CancerNCT02151760
Metastatic Pros...
18F-DCFPyL
18 Years - 100 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate CancerNCT06359821
Metastatic Pros...
ZA-001
18 Years - 100 YearsSichuan University
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCNCT04846478
Metastatic Pros...
Metastatic Cast...
Talazoparib
Tazemetostat
18 Years - Dana-Farber Cancer Institute
Carboplatin or Olaparib for BRcA Deficient Prostate CancerNCT04038502
Metastatic Cast...
BARD1, BRCA1, B...
RAD51B, RAD51C,...
Carboplatin
Olaparib
18 Years - VA Office of Research and Development
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or EnzalutamideNCT04335682
Metastatic Pros...
Prostate Cancer...
Prostate Cancer
Castrate Resist...
Darolutamide
Enzalutamide
18 Years - Alliance Foundation Trials, LLC.
Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate CancerNCT00441571
Metastatic Pros...
177Lu-CYT-500
18 Years - Cytogen Corporation
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate CancerNCT04220983
Metastatic Pros...
MR-Guided Prost...
18 Years - 90 YearsWeill Medical College of Cornell University
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the DiseaseNCT01933022
Metastatic Pros...
Eligard
18 Years - Astellas Pharma Inc
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerNCT01834209
Prostate Neopla...
Abiraterone ace...
Prednisone or p...
18 Years - Janssen Research & Development, LLC
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerNCT01981122
Metastatic Pros...
sipuleucel-T
enzalutamide
18 Years - Dendreon
Study of ORIC-944 in Patients With Metastatic Prostate CancerNCT05413421
Metastatic Pros...
Neuroendocrine ...
ORIC-944
18 Years - ORIC Pharmaceuticals
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE TrialNCT06040125
PROSTATE CANCER
Metastatic Pros...
Metastatic Pros...
Supervised Circ...
18 Years - Dana-Farber Cancer Institute
Psma Intensity Can be Altered by Androgen and Phospho-SrC ObstructionNCT04925648
Metastatic Pros...
Dasatinib
Darolutamide
18 Years - St Vincent's Hospital, Sydney
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerNCT01981122
Metastatic Pros...
sipuleucel-T
enzalutamide
18 Years - Dendreon
Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)NCT03050866
Circulating Tum...
Metastatic Pros...
Cabazitaxel
Antihistamine
Corticosteroid
H2 antagonist
Antiemetic
18 Years - Erasmus Medical Center
CMAB vs IMAB in Metastatic Prostate CancerNCT00255268
Metastatic Pros...
Goserelin
Bicalutamide
18 Years - AstraZeneca
A Journey Into Participation Patterns Among Metastatic Prostate Cancer PatientsNCT06009549
Metastatic Pros...
18 Years - Power Life Sciences Inc.
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerNCT05189457
Prostate Cancer
Stage IV Prosta...
Luteinizing Hor...
New Hormonal Ag...
Docetaxel
Tislelizumab
18 Years - H. Lee Moffitt Cancer Center and Research Institute
TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate CancerNCT05582772
Metastatic Pros...
GA+M Interventi...
RSM interventio...
GA+RSM interven...
65 Years - University Health Network, Toronto
Study of 177Lu-PSMA-0057 in Metastatic Prostate CancerNCT06050239
Metastatic Pros...
177Lu-PSMA-0057
18 Years - Nanjing First Hospital, Nanjing Medical University
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate CancerNCT04887506
Metastatic Cast...
Metastatic Cast...
Metastatic Pros...
TAVT-45
Zytiga
Prednisone
18 Years - Tavanta Therapeutics
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerNCT00055471
Prostatic Neopl...
Metastases, Neo...
ZD4054 10 mg
ZD4054 15 mg
ZD4054 22.5 mg
18 Years - AstraZeneca
Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate CancerNCT04556045
Metastatic Pros...
Exercise therap...
18 Years - Case Comprehensive Cancer Center
TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate CancerNCT05582772
Metastatic Pros...
GA+M Interventi...
RSM interventio...
GA+RSM interven...
65 Years - University Health Network, Toronto
A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsNCT04478279
Glioblastoma
Melanoma Stage ...
Breast Cancer
Prostate Cancer
Glioblastoma Mu...
GBM
Brain Cancer
Metastatic Brea...
Metastatic Mela...
Metastatic Pros...
Melanoma Recurr...
Prostate Cancer...
Recurrent Gliob...
Newly Diagnosed...
ST101
Temozolomide
Radiation
18 Years - Sapience Therapeutics
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.NCT05917470
Metastatic Cast...
ONCT-534
18 Years - Oncternal Therapeutics, Inc
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate CancerNCT02446405
Prostatic Neopl...
Enzalutamide
NSAA
LHRHA or Surgic...
18 Years - University of Sydney
Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate CancerNCT01815515
Metastatic Pros...
18F-DCFBC
18 Years - 100 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4)NCT02730338
Metastatic Pros...
High intensity ...
Psychosocial su...
18 Years - Movember Foundation
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007
Metastatic Cast...
Metastatic Cast...
abiraterone
enzalutamide
docetaxel
apalutamide
cabazitaxel
Radium-223
Lutetium-177
degarelix
goserelin
leuprorelin
triptorelin
18 Years - Pfizer
Biomarkers of Bone Resorption in Metastatic Prostate CancerNCT01233557
Metastatic Pros...
40 Years - 80 YearsUniversity of Aberdeen
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPCNCT05771896
Metastatic Pros...
Darolutamide
Radium-223
18 Years - GenesisCare USA
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate CancerNCT00942578
Metastatic Pros...
Bevacizumab
Lenalidomide
Docetaxel
Prednisone
18 Years - 100 YearsNational Institutes of Health Clinical Center (CC)
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsNCT03248570
Castration Resi...
Metastatic Pros...
Pembrolizumab
Chemotherapy
18 Years - University of California, San Francisco
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerNCT01957436
Metastatic Pros...
abiraterone ace...
radiotherapy
Androgen Depriv...
Docetaxel
18 Years - UNICANCER
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerNCT06303713
Prostate Cancer
Metastatic Pros...
Metastatic Cast...
Carboplatin
177Lu-PSMA-617
18 Years - Dana-Farber Cancer Institute
Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)NCT05404139
Metastatic Pros...
Enzalutamide
Standard of Car...
18 Years - 100 YearsUniversity Health Network, Toronto
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.NCT03497377
Metastatic Pros...
18F-DCFPyL Inje...
18F-NaF
18 Years - 100 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly PatientsNCT01254513
Prostate Cancer
Docetaxel every...
Docetaxel weekl...
75 Years - UNICANCER
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate CancerNCT02066961
Prostate Cancer
Castration-resi...
Metastatic Pros...
- Astellas Pharma Inc
mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate CancerNCT04545697
Metastatic Pros...
Medcorder
18 Years - University of California, San Francisco
Study of AZD0754 in Participants With Metastatic Prostate CancerNCT06267729
Metastatic Pros...
AZD0754
18 Years - 130 YearsAstraZeneca
Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate CancerNCT01923727
Metastatic Pros...
[89Zr]Df-IAB2M
18 Years - ImaginAb, Inc.
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate CancerNCT03230734
Metastatic Cast...
Radium-223
Docetaxel
18 Years - Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)NCT02380274
Prostate Cancer
Castration-resi...
Metastatic Pros...
18 Years - Astellas Pharma Inc
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPCNCT03432949
Metastatic Pros...
Dexamethasone p...
- University Health Network, Toronto
68Ga-PSMA PET/CT for Ra223 AssessmentNCT04951817
Metastatic Pros...
Ga-68 PSMA liga...
40 Years - 85 YearsChang Gung Memorial Hospital
ZANTE: Zometa and Taxotere in Hormone Refractory Prostate CancerNCT00415779
Metastatic Pros...
docetaxel
zoledronic acid
18 Years - National Cancer Institute, Naples
Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate CancerNCT01296139
Prostate Cancer
Ferumoxytol
18 Years - 100 YearsNational Institutes of Health Clinical Center (CC)
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the DiseaseNCT01933022
Metastatic Pros...
Eligard
18 Years - Astellas Pharma Inc
Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerNCT05617885
Metastatic Pros...
Non-metastatic ...
Prostate Cancer
Darolutamide
Abemaciclib
GNRH-A Leuproli...
GNRH-A Gosereli...
Degarelix
18 Years - Dana-Farber Cancer Institute
Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)NCT05404139
Metastatic Pros...
Enzalutamide
Standard of Car...
18 Years - 100 YearsUniversity Health Network, Toronto
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)NCT02500901
Metastatic Pros...
Enzalutamide
Niraparib
18 Years - Hoosier Cancer Research Network
Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer PatientsNCT01677897
Metastatic Pros...
Metformin
18 Years - 90 YearsKantonsspital Graubünden
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerNCT05367440
Metastatic Pros...
AZD5305
Enzalutamide
Abiraterone Ace...
Darolutamide
Apalutamide
18 Years - 130 YearsAstraZeneca
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsNCT02376296
Prostate Cancer
docetaxel
Blood draws
18 Years - Saladax Biomedical, Inc.
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC PatientsNCT06350825
Metastatic Pros...
Therapy, Direct...
Cytoreductive p...
ADT+second-gene...
18 Years - 75 YearsThe First Affiliated Hospital with Nanjing Medical University
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: